Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Cakir B, Agostini H, Lange C: [Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists]. Ophthalmologe, 2019; 116 (2): 189-200. : http://dx.doi.org/10.1007/s00347-018-0785-y
  • Ehlken C, Guichard MM, Schlunck G, Buhler AD, Martin G, Agostini HT: Expression of Angiogenic and Inflammatory Factors in Choroidal Neovascularisation-Derived Retinal Pigment Epithelium. Ophthalmic Res, 2019; 61: 174-182. : http://dx.doi.org/10.1159/000481260
  • Baumgarten S, Schiller P, Hellmich M, Walter P, Agostini H, Junker B, Helbig H, Lommatzsch A, Mazinani B: Vitrectomy with and without encircling band for pseudophakic retinal detachment with inferior breaks: VIPER Study Report No. 3. Graef Arch Clin Exp, 2018; 256 (11): 2069-2073. : http://dx.doi.org/10.1007/s00417-018-4106-6
  • Bruender MC, Benjamin N, Agostini HT, Stahl A, Ehlken C: Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies. Graef Arch Clin Exp, 2018; 256 (9): 1565-1571. : http://dx.doi.org/10.1007/s00417-018-4021-x
  • Ehlken C, Bohringer D, Agostini HT, Grundel B, Stech M: Potential selection bias in candidates for stereotactic radiotherapy for neovascular AMD. Graef Arch Clin Exp, 2018; 256 (1): 105-111. : http://dx.doi.org/10.1007/s00417-017-3849-9
  • Ehlken C, Helms M, Bohringer D, Agostini HT, Stahl A: Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol, 2018; 12: 13-20. : http://dx.doi.org/10.2147/OPTH.S151611
  • Ehlken C, Wilke T, Bauer-Steinhusen U, Agostini HT, Hasanbasic Z, Muller S: TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study. Retina-j Ret Vit Dis, 2018; 38 (6): 1134-1144. : http://dx.doi.org/10.1097/IAE.0000000000001681
  • Maier MM, Nasseri A, Framme C, Bohnacker S, Becker MD, Heinrich D, Agostini H, Feucht N, Lohmann CP, Hattenbach LO: [Intraoperative Optical Coherence Tomography in Vitreoretinal Surgery: Clinical Experiences and Future Developments]. Klin Monatsbl Augenh, 2018; 235 (9): 1028-1034. : http://dx.doi.org/10.1055/s-0043-106304
  • Martin G, Conrad D, Cakir B, Schlunck G, Agostini H: Gene expression profiling in a mouse model of retinal vein occlusion induced by laser treatment reveals a predominant inflammatory and tissue damage response Plos One, 2018; 13: e0191338-23. : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191338
  • Melzer C, Ziemssen F, Eter N, Brinkmann C, Agostini H, Haeusser-Fruh G, Rose U, Schargus M, Lorenz K, Holz FG, Schmitz-Valckenberg S: Design and Baseline Characteristics of the HELP Study: An Extended and Long-Term Observation of Pathological Myopia in Caucasians. Ophthalmologica, 2018; 240 (3): 167-178. : http://dx.doi.org/10.1159/000489180
  • Reuer T, Schneider AC, Cakir B, Buhler AD, Walz JM, Lapp T, Lange C, Agostini H, Schlunck G, Cursiefen C, Reinhard T, Bock F, Stahl A: Semaphorin 3F Modulates Corneal Lymphangiogenesis and Promotes Corneal Graft Survival. Invest Ophth Vis Sci, 2018; 59 (12): 5277-5284. : http://dx.doi.org/10.1167/iovs.18-24287
  • Agostini HT, Bopp S, Feltgen N: [Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration]. Ophthalmologe, 2017; 114 (5): 476-480. : http://dx.doi.org/10.1007/s00347-017-0487-x
  • Cakir B, Reich M, Lang SJ, Buhler A, Stahl A, Bohringer D, Agostini H, Lange C: [Possibilities and Limitations of OCT-Angiography in Patients with Central Serous Chorioretinopathy]. Klin Monatsbl Augenh, 2017; 234 (9): 1161-1168. : http://dx.doi.org/10.1055/s-0043-102576
  • Lang SJ, Evers C, Cakir B, Ludwig F, Lange C, Agostini H: [Optical Coherence Tomography Angiography in Diagnosis and Post-Treatment Assessment of Hemangioblastomas in Hippel-Lindau Disease]. Klin Monatsbl Augenh, 2017; 234 (9): 1146-1153. : http://dx.doi.org/10.1055/s-0043-102574
  • Luebke J, Reinhard T, Agostini H, Boehringer D, Eberwein P: Long-term follow-up after scleral lens fixation in patients with Marfan syndrome Bmc Ophthalmol, 2017; 17 (online): 235. : http://dx.doi.org/10.1186/s12886-017-0625-x
  • Muller S, Ehlken C, Bauer-Steinhusen U, Lechtenfeld W, Hasanbasic Z, Agostini H, Wilke T: Treatment of age-related neovascular macular degeneration: the patient's perspective. Graef Arch Clin Exp, 2017; 255 (11): 2237-2246. : http://dx.doi.org/10.1007/s00417-017-3739-1
  • Sun Y, Liegl R, Gong Y, Buhler A, Cakir B, Meng SS, Burnim SB, Liu CH, Reuer T, Zhang P, Walz JM, Ludwig F, Lange C, Agostini H, Bohringer D, Schlunck G, Smith LEH, Stahl A: Sema3f Protects Against Subretinal Neovascularization In Vivo. EBioMedicine, 2017; 18: 281-287. : http://dx.doi.org/10.1016/j.ebiom.2017.03.026
  • Walter P, Hellmich M, Baumgarten S, Schiller P, Limburg E, Agostini H, Pielen A, Helbig H, Lommatzsch A, Rossler G, Mazinani B: Vitrectomy with and without encircling band for pseudophakic retinal detachment: VIPER Study Report No 2-main results. Brit J Ophthalmol, 2017; 101 (6): 712-718. : http://dx.doi.org/10.1136/bjophthalmol-2016-309240
  • Wecker T, Ehlken C, Buhler A, Lange C, Agostini H, Bohringer D, Stahl A: Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Brit J Ophthalmol, 2017; 101 (3): 353-359. : http://dx.doi.org/10.1136/bjophthalmol-2016-308668
  • Bertram B, Lemmen K-D, Agostini H, Ziemssen F, Hammes H-P, Landgraf R: Netzhautkomplikationen bei Diabetes Diabetologe, 2016; 12: 509-521.
  • Bucher F, Walz JM, Buhler A, Aguilar E, Lange C, Diaz-Aguilar S, Martin G, Schlunck G, Agostini H, Friedlander M, Stahl A: CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy. Invest Ophth Vis Sci, 2016; 57 (10): 4017-4026. : http://dx.doi.org/10.1167/iovs.15-18508
  • Buhler AD, Bucher F, Augustynik M, Wohrl J, Martin G, Schlunck G, Agostini H, Bohringer D, Putz G, Stahl A: Systemic confounders affecting serum measurements of omega-3 and -6 polyunsaturated fatty acids in patients with retinal disease. Bmc Ophthalmol, 2016; 16 (1) (online): 159-159. : http://dx.doi.org/10.1186/s12886-016-0335-9
  • Cakir B, Fischer F, Ehlken C, Buhler A, Stahl A, Schlunck G, Bohringer D, Agostini H, Lange C: Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graef Arch Clin Exp, 2016; 254 (11): 2151-2157. : http://dx.doi.org/10.1007/s00417-016-3373-3
  • Hattenbach LO, Framme C, Junker B, Pielen A, Agostini H, Maier M: [Intraoperative real-time OCT in macular surgery]. Ophthalmologe, 2016; 113 (8): 656-662. : http://dx.doi.org/10.1007/s00347-016-0297-6
  • Junker B, Maier M, Agostini H, Hattenbach LO, Pielen A, Framme C: [Intraoperative optical coherence tomography in retinal detachment]. Ophthalmologe, 2016; 113 (8): 663-667. : http://dx.doi.org/10.1007/s00347-016-0321-x
  • Lang SJ, Cakir B, Evers C, Ludwig F, Lange CA, Agostini HT: Value of Optical Coherence Tomography Angiography Imaging in Diagnosis and Treatment of Hemangioblastomas in von Hippel-Lindau Disease. Osli Retina, 2016; 47 (10): 935-946. : http://dx.doi.org/10.3928/23258160-20161004-07
  • Lemmen K, Bertram B, Agostini H, Spital G, Hammes HP: Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulopathie – ein Update Z prakt Augenheilkd, 2016; 37: 567-577. (download: https://www.diabetes-auge.de/images/downloads/ZPA_12-2016.pdf)
  • Mazinani B, Baumgarten S, Schiller P, Agostini H, Helbig H, Limburg E, Hellmich M, Walter P: Vitrectomy with or without encircling band for pseudophakic retinal detachment: a multi-centre, three-arm, randomised clinical trial. VIPER Study Report No. 1-design and enrolment. Brit J Ophthalmol, 2016; 100: 405-410. : http://dx.doi.org/10.1136/bjophthalmol-2015-306732
  • Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T: Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment. Ophthalmology, 2016; 123 (4): 876-883. : http://dx.doi.org/10.1016/j.ophtha.2015.12.001
  • Ziemssen F, Lemmen K, Bertram B, Hammes HP, Agostini H: [National guidelines for treatment of diabetic retinopathy : Second edition of the national guidelines for treatment of diabetic retinopathy]. Ophthalmologe, 2016; 113 (7): 623-638. : http://dx.doi.org/10.1007/s00347-016-0315-8
  • Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F: Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous, 2016; 2 (online): 16. : http://dx.doi.org/10.1186/s40942-016-0041-z
  • Ehlken C, Grundel B, Michels D, Junker B, Stahl A, Schlunck G, Hansen LL, Feltgen N, Martin G, Agostini HT, Pielen A: Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion. Plos One, 2015; 10 (5) (online): e0126859-e0126859. : http://dx.doi.org/10.1371/journal.pone.0126859
  • Schmucker CM, Rücker G, Sommer H, Virgili G, Loke YK, Oeller P, Agostini H, Ehlken C: Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Plos One, 2015; 10 (9) (online): e0137866. : http://dx.doi.org/10.1371/journal.pone.0137866
  • Ehlken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A: Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye, 2014; 28 (5): 538-545. : http://dx.doi.org/10.1038/eye.2014.64
  • Pielen A, Guerra NI, Bohringer D, Junker B, Buhler AD, Stahl A, Agostini HT, Ehlken C: Intra- and postoperative risks and complications of small-gauge (23-G) versus conventional (20-G) vitrectomy for macular surgery. Eur J Ophthalmol, 2014; 24 (5): 778-785. : http://dx.doi.org/10.5301/ejo.5000461
  • Bucher F, Stahl A, Agostini HT, Martin G: Hyperoxia causes reduced density of retinal astrocytes in the central avascular zone in the mouse model of oxygen-induced retinopathy. Mol Cell Neurosci, 2013; 56: 225-233. : http://dx.doi.org/10.1016/j.mcn.2013.06.001
  • Buehler A, Sitaras N, Favret S, Bucher F, Berger S, Pielen A, Joyal JS, Juan AM, Martin G, Schlunck G, Agostini HT, Klagsbrun M, Smith LE, Sapieha P, Stahl A: Semaphorin 3F forms an anti-angiogenic barrier in outer retina. Febs Lett, 2013; 587 (11): 1650-1655. : http://dx.doi.org/10.1016/j.febslet.2013.04.008
  • Buhler A, Berger S, Bengsch F, Martin G, Han H, Vierkotten S, Pielen A, Boehringer D, Schlunck G, Fauser S, Agostini HT, Reinheckel T, Stahl A: Cathepsin proteases promote angiogenic sprouting and laser-induced choroidal neovascularisation in mice. Exp Eye Res, 2013; 115: 73-78. : http://dx.doi.org/10.1016/j.exer.2013.06.014
  • Eberwein P, Haeupler A, Kuepper F, Wagner D, Kern WV, Muntau B, Racz P, Agostini H, Poppert S: Human infection with marten tapeworm. Emerg Infect Dis, 2013; 19 (7): 1152-1154. : http://dx.doi.org/10.3201/eid1907.121114
  • Gross N, Ranjbar M, Evers C, Hua J, Martin G, Schulze B, Michaelis U, Hansen LL, Agostini HT: Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol Vis, 2013; 19: 54-61.
  • Stahl A, Stumpp MT, Schlegel A, Ekawardhani S, Lehrling C, Martin G, Gulotti-Georgieva M, Villemagne D, Forrer P, Agostini HT, Binz HK: Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis, 2013; 16 (1): 101-111. : http://dx.doi.org/10.1007/s10456-012-9302-0
  • Viiri J, Amadio M, Marchesi N, Hyttinen JM, Kivinen N, Sironen R, Rilla K, Akhtar S, Provenzani A, D'Agostino VG, Govoni S, Pascale A, Agostini H, Petrovski G, Salminen A, Kaarniranta K: Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells. Plos One, 2013; 8 (7): e69563-e69563. : http://dx.doi.org/10.1371/journal.pone.0069563
  • Ehlken C, Martin G, Stahl A, Agostini HT: Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab. Arch Ophthalmol-chic, 2012; 130 (9): 1226-1227. : http://dx.doi.org/10.1001/archophthalmol.2012.112
  • Hua J, Gross N, Schulze B, Michaelis U, Bohnenkamp H, Guenzi E, Hansen LL, Martin G, Agostini HT: In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. Mol Vis, 2012; 18: 1045-1054.
  • Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK: A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. Plos One, 2012; 7 (8) (online): e42701. : http://dx.doi.org/10.1371/journal.pone.0042701
  • Stahl A, Lagreze WA, Agostini HT: [Pathogenesis of retinopathy of prematurity]. Ophthalmologe, 2012; 109 (12): 1174-1181. : http://dx.doi.org/10.1007/s00347-012-2616-x
  • Ehlken C, Martin G, Lange C, Gogaki EG, Fiedler U, Schaffner F, Hansen LL, Augustin HG, Agostini HT: Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol, 2011; 89: 82-90. : http://dx.doi.org/10.1111/j.1755-3768.2009.01609.x
  • Ehlken C, Rennel ES, Michels D, Grundel B, Pielen A, Junker B, Stahl A, Hansen LL, Feltgen N, Agostini HT, Martin G: Levels of VEGF but not VEGF(165b) are Increased in the Vitreous of Patients With Retinal Vein Occlusion. Am J Ophthalmol, 2011; 152 (2): 298-303.e1. : http://dx.doi.org/10.1016/j.ajo.2011.01.040
  • Fischer F, Martin G, Agostini HT: Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy. J Neuroinflamm, 2011; 8 (1): 120. : http://dx.doi.org/10.1186/1742-2094-8-120
  • Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M: Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Brit J Ophthalmol, 2011; 95: 308-317. : http://dx.doi.org/10.1136/bjo.2009.178574
  • Stahl A, Agostini H, Jandeck C, Lagreze W: [Pharmacological treatment for retinopathy of prematurity]. Ophthalmologe, 2011; 108 (8): 777-85; quiz 786. : http://dx.doi.org/10.1007/s00347-011-2371-4
  • Callizo J, Agostini HT: [siRNA in macular degeneration.] Ophthalmologe, 2010; 107 (11): 1077-1080. : http://dx.doi.org/10.1007/s00347-010-2230-8
  • Eberwein P, Reinhard T, Agostini H, Poloschek CM, Guthoff R, Auw-Haedrich C: [Intensive intracorneal keloid formation in a case of Peters plus syndrome and in Peters anomaly with maximum manifestation.] Ophthalmologe, 2010; 107 (2): 178-181. : http://dx.doi.org/10.1007/s00347-009-2014-1
  • Feltgen N, Pielen A, Hansen L, Bertram B, Agostini H, Jaissle GB, Hoerauf H, Stahl A: [Intravitreal drug therapy for retinal vein occlusion-pathophysiological mechanisms and routinely used drugs] Klin Monatsbl Augenh, 2010; 227 (9): 681-693. : http://dx.doi.org/10.1055/s-0029-1245606
  • Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ: VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophth Vis Sci, 2010; 51 (8): 4273-4281. : http://dx.doi.org/10.1167/iovs.09-4296
  • Ness T, Feltgen N, Agostini H, Bohringer D, Lubrich B: Toxic vitreitis outbreak after intravitreal injection. Retina-j Ret Vit Dis, 2010; 30 (2): 332-338.
  • Pieh C, Kruger M, Lagreze WA, Gimpel C, Buschbeck C, Zirrgiebel U, Agostini HT: Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest Ophth Vis Sci, 2010; 51 (7): 3709-3713. : http://dx.doi.org/10.1167/iovs.09-4723
  • Pielen A, Junker B, Hansen L, Agostini H, Feltgen N: [Clinical diagnostics and therapy for non-arteritic central retinal artery occlusion] Klin Monatsbl Augenh, 2010; 227 (9): 712-720. : http://dx.doi.org/10.1055/s-0029-1245660
  • Schmidt D, Agostini H, Schumacher M: Twenty-seven years follow-up of a patient with congenital retinocephalofacial vascular malformation syndrome and additional congenital malformations (Bonnet-Dechaume-Blanc syndrome or Wyburn-Mason syndrome). Eur J Med Res, 2010; 15 (2): 88-91.
  • Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M: Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol, 2010; 21 (3): 218-226. : http://dx.doi.org/10.1097/ICU.0b013e3283386783
  • Stahl A, Buchwald A, Martin G, Junker B, Chen J, Hansen LL, Agostini HT, Smith LE, Feltgen N: Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina-j Ret Vit Dis, 2010; 30 (9): 1524-1529. : http://dx.doi.org/10.1097/IAE.0b013e3181d37539
  • Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N: Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol, 2010; 20: 180-185.
  • Auw-Haedrich C, Agostini H, Clausen I, Reinhard T, Eberwein P, Schorderet DF, Gruenauer-Kloevekorn C: A corneal dystrophy associated with transforming growth factor beta-induced Gly623Asp mutation an amyloidogenic phenotype. Ophthalmology, 2009; 116 (1): 46-51. : http://dx.doi.org/10.1016/j.ophtha.2008.08.050
  • Lange C, Ehlken C, Stahl A, Martin G, Hansen L, Agostini HT: Kinetics of retinal vaso-obliteration and neovascularisation in the oxygen-induced retinopathy (OIR) mouse model. Graef Arch Clin Exp, 2009; 247 (9): 1205-1211. : http://dx.doi.org/10.1007/s00417-009-1116-4
  • Stahl A, Boeker M, Ehlken C, Agostini H, Reinhard T: [Evaluation of an Internet-based e-learning ophthalmology module for medical students.] Ophthalmologe, 2009; 106: 999-1005. : http://dx.doi.org/10.1007/s00347-009-1916-2
  • Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT: Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graef Arch Clin Exp, 2009; 247 (6): 767-773. : http://dx.doi.org/10.1007/s00417-009-1058-x
  • Agostini H, Feltgen N, Hansen L: Antiangiogene Therapie am Auge – bewährte und neue Therapieansätze Klin Monatsbl Augenh, 2008; 225: 39-43.
  • Pieh C, Agostini H, Buschbeck C, Krüger M, Schulte-Mönting J, Zirrgiebel U, Drevs J, Lagrèze W: VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: Relationship to retinopathy of prematurity. Brit J Ophthalmol, 2008; 92 (5): 689-693. : http://dx.doi.org/10.1136/bjo.2007.128371
  • Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, Agostini HT: Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. Febs Lett, 2008; 582 (20): 3097-3102. : http://dx.doi.org/10.1016/j.febslet.2008.08.005
  • Agostini H: Von-Hippel-Lindau-Syndrom – eine interdisziplinäre Herausforderung. Ophthalmologe, 2007; 104: 105-106.
  • Agostini H: Von Hippel-Lindau-Syndrom. Spektrum Augenheilkd, 2007; 21 (5): 269-270.
  • Feltgen N, Agostini H, Auw-Haedrich C, Hansen LL: Histopathologic findings after retinal endovascular lysis in central retinal vein occlusion. Brit J Ophthalmol, 2007; 91 (4): 558-559.
  • Feltgen N, Junker B, Agostini H, Hansen LL: Retinal endovascular lysis in ischemic central retinal vein occlusion: 1-year results of a pilot study. Ophthalmology, 2007; 114 (4): 716-723.
  • Joussen AM, Weiss C, Bauer D, Hilgers RD, Time Study Group (Hansen, Agostini): Triamcinolone versus inner-limiting membrane peeling in persistent diabetic macular edema (TIME study): design issues and implications. Graef Arch Clin Exp, 2007; 245 (12): 1781-1787.
  • Junker B, Schmidt D, Agostini H: Okuläre Manifestation des Von-Hippel-Lindau-Syndroms Ophthalmologe, 2007; 104: 107-113.
  • Junker B, Schmidt D, Agostini H: Angiomatosis retinae – Okuläre Manifestation des von-Hippel-Lindau-Syndroms Spektrum Augenheilkd, 2007; 21 (5): 262-268.
  • Kuiper E, Ehlken C, Lambert V, Roestenberg P, Lyons K, Agostini H, Rakic JM, Klaassen I, Van Noorden C, Goldschmeding R, Schlingemann R: Connective tissue growth factor (CTGF) is not involved in angiogenesis in knock out mouse models. J Histochem Cytochem, 2007; 55 (11): 1139-1147.
  • Lange C, Ehlken C, Martin G, Konzok K, Moscoso Del Prado J, Hansen LL, Agostini H: Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res, 2007; 85 (3): 323-327.
  • Rosenthal R, Heimann H, Agostini H, Martin G, Hansen LL, Strauss O: Ca2+ channels in retinal pigment epithelial cells regulate vascular endothelial growth factor secretion rates in health and disease. Mol Vis, 2007; 13: 443-456.
  • Schmidt D, Agostini H: Angiomatosis retinae. Eine ophthalmologische Herausforderung. Klin Monatsbl Augenh, 2007; 224: 905-921.
  • Stahl A, Agostini H, Hansen LL, Feltgen N: Bevacizumab in retinal vein occlusion – results of a prospective case follow-up study. Graef Arch Clin Exp, 2007; 245: 1429-1436.
  • Stahl A, Agostini H, Hansen LL, Feltgen N: Bevacizumab in retinal vein occlusion-results of a prospective case series. Graef Arch Clin Exp, 2007; 245 (10): 1429-1436. : http://dx.doi.org/10.1007/s00417-007-0569-6
  • Agostini H: Philip L. Penfold, Jan M. Provis: Macular degeneration Graef Arch Clin Exp, 2006; 244 (2): 276-277.
  • Feltgen N, Herrmann J, Sammain A, Agostini H, Hansen L: Arterio-venous dissection after isovolaemic haemodilution in branch retinal vein occlusion: a nonrandomised prospective study. Graef Arch Clin Exp, 2006; 244 (7) (online): 829-835.
  • Kube, T., Sutter, M., Trittler, R., Feltgen, N., Hansen, L. L., Agostini, H. T.: Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone Graef Arch Clin Exp, 2006; 244 (11): 1385-1390.
  • Richter B, Agostini HT, Boedeker C, Reinhard T, Laszig R, Hansen LL: OSCE nach Einführung der 5.AO - ein erster Erfahrungsbericht in den Fächern HNO- und Augenheilkunde Zeitschrift für Allgemeinmedizin, 2006; 82 (8): 343-348.
  • Agostini HT, Fiedler U, Boden K, Unsöld A, Martin G, Esser N, Marmé D, Hansen LL: A single local injection of recombinant VEGF Receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse Curr Eye Res, 2005; 30: 249-257.
  • Eberwein P, Hansen LL, Agostini HT: Genotypes of JC virus, DNA of cytomegalovirus, and proviral DNA of human immunodeficiency virus in eyes of acquired immunodeficiency syndrome patients. J Neurovirol, 2005; 11 (1): 58-65.
  • Maier P, Unsoeld AS, Junker B, Martin G, Drevs J, Hansen LL, Agostini HT: Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graef Arch Clin Exp, 2005; 243: 593-600.
  • Martin G, Agostini H, Hansen L: Light emitting diode microscope illumination for green fluorescent protein or fluorescein isothiocyanate epifluorescence Biotechniques, 2005; 38 (2): 205-206.
  • Cui x, Wang JC, Deckhut A, Joseph B, Eberwein P, Cubitt CL, Ryschkewitsch CF, Agostini HT, Stoner GL: Chinese and Mongolian strains of JC virus are Afro-Asiatic in origin, but are phylogenetically distinct from basal Papua New Guinea strains, as well as from the Korean and Japanese strains which predominate in Native Americans J Mol Evol, 2004; 58 (5): 568-583.
  • Maier P, Hansen LL, Agostini HT: Severe retinal damage after macular hole surgery with extensive indocyanine green-assisted internal limiting membrane peeling Eye, 2004; 18: 538-539.
  • Martin G, Schlunck G, Hansen LL, Agostini HT: Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Graef Arch Clin Exp, 2004; 242 (4): 321-326.
  • Unsöld A, Junker B, Mazitschek R, Martin G, Hansen L, Giannis A, Agostini H: Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice Mol Vis, 2004; 10: 468-475.
  • Agostini HT, Hansen LL: [Angioproliferative retinal disease caused by ischemia] Ophthalmologe, 2003; 100 (5): 371-377.
  • Fernandez-Cobo AF, Agostini HT, Britez G, Ryschkewitsch CF, Stoner GL: Strains of JC Virus in Amerind-Speakers of North America (Salish) and South America (Guarini), Na-Dene-Speakers of New Mexico (Navajo), and Modern Japanese Suggest Links Through an Ancestral Asian Population. Am J Phys Anthropol, 2002; 118: 154-168.
  • Schlunck G, Martin G, Agostini HT, Camatta G, Hansen LL: Cultivation of retinal pigment epithelial cells from human choroidal neovascular membranes in age related macular degeneration. Exp Eye Res, 2002; 74 (5): 571-576.
  • Yanagihara R, Nerurkar VR, Scheirich I, Agostini HT, Mgone CS, Cui X, Jobes DV, Cubitt CL, Ryschkewitsch CF, Hrdy DB, Friedlaender JS, Stoner GL: JC virus genotypes in the western Pacific suggest Asian mainland relationships and virus association with early population movements. Hum Biol, 2002; 74 (3): 473-488.
  • Agostini HT, Deckhut A, Jobes DV, Girones R, Schlunck G, Prost MG, Frias C, Perez-Trallero E, Ryschkewitsch CF, Stoner GL: Genotypes of JC virus in East, Central and Southwest Europe. Journal of General Virology, 2001; 82: 1221-1331.
  • Cubitt CL, Cui X, Agostini HT, Nerurkar VR, Scheirich I, Yanagihara R, Ryschkewitsch CF, Stoner GL: Predicted amino acid sequences for 100 JCV strains. J Neurovirol, 2001; 7 (4): 339-344.
  • Jobe DV, Friedlaender JS, Mgone CS, Agostini HT, Koki G, Yanagihara R, Ng TCN, Chima SC, Ryschkewitsch CF, Stoner GL: New JC virus (JCV) genotypes from papua new guinea and micronesia (type 8 and type 2E) and evolutionary analysis of 32 complete JCV genomes. Arch Virol, 2001; 146 (11): 2097-2113.
  • Agostini HT, Mittelviefhaus H: Sectorial corneal degeneration after glass splinter injury . Ophthalmologe, 2000; 97(6): 442-443.
  • Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW, Singer EJ, Komoly S, Stoner GL: Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy. Journal of Neurovirology, 2000; 6 Suppl. 2: S101-S108.
  • Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C: Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole letter . British Journal of Ophthalmology, 2000; 84(8): 932-933.
  • Ryschkewitsch CF, Friedlaender JS, Mgone CS, Jobes DV, Agostini HT, Chima SC, Alpers MP, Koki G, Yanagihara R, Stoner GL: Human polyomavirus JC variants in Papua New Guinea and Guam reflect ancient population settlement and viral evolution. Microbes Infect, 2000; 2: 987-996.
  • Chima SC, Agostini HT, Ryschkewitsch CF, Lucas SB, Stoner GL: Progressive multifocal leukoencephalopathy and JC virus genotypes in West African patients with acquired immunodeficiency syndrome: a pathologic and DNA sequence analysis of 4 cases Archives of Pathology & Laboratory Medicine, 1999; 123: 395-403.
  • Agostini H, Ryschkewitsch CF, Singer EJ, Stoner GL: JC Virus Type 2B is Found More Frequently in Brain Tissue of Progressive Multifocal Leukoencephalopathy Patients Than in Urine From Controls. J. Human. Virol., 1998; 1: 200-206.
  • Agostini H, Ryschkewitsch CF, Stoner GL: REARRANGEMENTS OF ARCHETYPAL REGULATORY REGIONS IN JC VIRUS GENOMES FROM URINE Res Virology, 1998; 149: 163-170.
  • Agostini HT, Ryschkewitsch CF, Stoner GL: JC VIRUS TYPE 1 HAS MULTIPLE SUBTYPES - THREE NEW COMPLETE GENOMES. Journal of General Virology, 1998; 79: 801-805.
  • Agostini HT, Ryschkewitsch CF, Stoner GL: The Complete Genome of JC Virus Type 6 from the Brain of an African-American with Progressive Multifocal Leukoencephalopathy (PML. J. Human Virology, 1998; 1: 267-272.
  • Stoner, G. L., Agostini, H. T., Ryschkewitsch, C. F., Mazlo, M., Gullotta, F., Wamukota, W., Lucas, S.: Detection of JC virus in two African cases of progressive multifocal leukoencephalopathy including identification of JCV type 3 in a Gambian AIDS patient Journal of Medical Microbiology, 1998; 47: 733-742.
  • Stoner GL, Agostini HT, Ryschkewitsch CF, Komoly S: JC VIRUS EXCRETED BY MULTIPLE SCLEROSIS PATIENTS AND PAIRED CONTROLS FROM HUNGARY. Multiple Sclerosis, 1998; 4: 45-48.
  • Agostini H, Ryschkewitsch CF, Brubaker GR, Shao J, Stoner GL: Five complete genomes of JC virus Type 3 from Africans and African Americans Arch Virol, 1997; 142: 637-655.
  • Agostini H, Ryschkewitsch CF, Mory R, Singer EJ, Stoner GL: JC virus (JCV) genotypes in brain tissue from patients with progressive multifocal leukoencephalopathy (PML) and in urine from controls without PML: Increased frequency of JCV Type 2 J Infect Dis, 1997; 176: 1-8.
  • Agostini H, Ryschkewitsch CF, Singer EJ, Stoner GL: JC virus regulatory region rearrangements and genotypes in progressive multifocal leukoencephalopathy: Two independent aspects of virus variation. J Gen Virol, 1997; 78: 659-664.
  • Agostini H, Shishido-Hara Y, Baumhefner RW, Ryschkewitsch CF, Stoner GL: JC Virus Type 2: Definition of subtypes based on DNA equence analysis of ten complete genomes. J Gen Virol, 1997; 79: 1143-1151.
  • Agostini H, Yanagihara R, Davis V, Ryschkewitsch CF, Stoner GL: Asian genotypes of JC virus in Native Americans and in a Pacific Island population: Markers of viral evolution and human migration Proc Natl Acad Sci, 1997; 94: 14542-14546.
  • Agostini HT, Ryschkewitsch CF, Singer EJ, Stoner GL: Co-infection with two JC virus genotypes in brain, cerebrospinal fluid or urinary tract detected by direct cycle sequencing of PCR products. J Neurovirol, 1996; 2 (4): 259-267.
  • Agostini HT, Ryschkewitsch CF, Stoner GL: Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol, 1996; 34 (1): 159-164.
  • Agostini H, Bräutigam P, Löffler KU: Subretinal tumor in a patient with a limited form of Wegener's granulomatosis. Acta Ophthalmol, 1995; 73: 460-463.
  • Agostini HT, Brubaker GR, Shao J, Levin A, Ryschkewitsch CF, Blattner WA, Stoner GL: BK virus and a new type of JC virus excreted by HIV-1 positive patients in rural Tanzania. Arch Virol, 1995; 140 (11): 1919-1934.
  • Agostini HT, Gerstenecker B, Haessler C, Braun DG, Brandner G, Hess RD: Monospecific polyclonal anti-anti-idiotypic antibodies to the carboxyterminal undecapeptide of the SV40 large tumour antigen. Scand J Immunol, 1995; 41 (3): 256-262.
  • Agostini HT, Stoner GL: Amplification of the complete polyomavirus JC genome from brain, cerebrospinal fluid and urine using pre-PCR restriction enzyme digestion. J Neurovirol, 1995; 1 (3-4): 316-320.
Reviews/Übersichtsartikel in wissenschaftlichen Fachzeitschriften:
  • Agostini H, Martin G, Ziemssen F: Pathomechanismen der diabetischen Retinopathie Diabetologe, 2018; 14 (8): 542-549. : https://doi.org/10.1007/s11428-018-0409-9
  • Bertram B, Lemmen K.-D., Agostini H, Ziemssen F, Hammes H.-P., Landgraf R: Retinopathie erfordert Teamarbeit Info Diabetologie, 2018; 12 (1): 35-41.
  • Ziemssen F, Roeck D, Marahrens L, Agostini H: Bildgebung der diabetischen Retinopathie Diabetologe, 2018; 14 (8): 550-556. : https://doi.org/10.1007/s11428-018-0410-3
  • Feltgen N, Hansen LL, Agostini H: [Treatment of Retinal Vein Occlusion - Is There Still a Role for Vitreoretinal Surgery?] Klin Monatsbl Augenh, 2017; 234 (9): 1103-1108. : http://dx.doi.org/10.1055/s-0043-111801
  • Agostini H, Hansen LL, Feltgen N: Die Behandlung des pseudophaken zystoiden Makulaödems. [Treatment of pseudophakic cystoid macular edema.] Ophthalmologe, 2007; 104 (5): 425-430.
  • Feltgen N, Agostini H, Hansen LL: Chirurgische Therapie retinaler Venenverschlüsse. Ophthalmologe, 2007; 104 (4): 279-284.
  • Agostini HT, Jobes DV, Chima SC, Ryschkewitsch CF, Stoner GL: Natural and pathogenic variation in the JC virus genome. Recent Res. Devel. Virol., 1999; 1: 683-701.
Monographien:
  • Michels S, Agostini H: Inhibition der Angiogenese in der AugenheilkundeUni-Med, 2007 (Science).
Buchbeiträge:
  • Agostini H, Martin G: Involvement of the Ephrin/Eph system in angioproliferative ocular disease. In: Retinal Vascular Disease Berlin-Heidelberg-New York: Springer, 2007; 73-76.
  • Stahl A, Boeker M, Agostini HT, Reinhard T: Interaktives E-Learning im Blockpraktikum Augenheilkunde In: Neue Medien als strategische Schrittmacher an der Universität Freiburg Freiburg: Verlag Universitätsbibliothek Freiburg, 2007.
  • Agostini HT, Funk J: Neovaskuläres Glaukom In: Rohrbach und Schlote (Hrsg.): Sekundarglaukome, 1. Auflage. Stuttgart: Schattauer-Verlag, 2004.
  • Agostini HT, Jobes DV, Stoner GL: Molecular Evolution and Epidemiology of JC Virus In: Kamel Khalili and Gerald L. Stoner (Hrsg.): Human Polymoaviruses. Molecular and Clinical Perspectives. New York: Wiley-Liss, 2001; 491-526.
Kurzbeiträge / short communications:
  • Ziemssen F, Agostini H: Re: Boyer et al.: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (Ophthalmology 2014;121:1904-14). Ophthalmology, 2015; 122 (3) (online): e20-e21. : http://dx.doi.org/10.1016/j.ophtha.2014.08.016
Konferenzbeiträge:
  • Agostini HT: Ephrin/Eph in proliferative retinopathy - lessons from a mouse model Ophthal Res, 2004; 36 Suppl. S1: 191 (EVER 2004), Karger (Hrsg).
  • Ehlken C, Martin G, Hansen LL, Agostini HT: Expression of EphrinB2 and EphB4 in a mouse model of oxygen-induced retinopathy 2004 (DOG). : http://www.egms.de/en/meetings/dog2004/04dog020.shtml
  • Kube T, Hansen L, Agostini H: FUNDUS IMAGING OF THE RETINAL VASCULAR DEVELOPMENT IN AN OXYGEN INDUCED MODEL OF PROLIFERATIVE RETINOPATHY 2004 (XVI. International Congress of Eye Research, Sydney, 29 August to 3 September 2004.). : http://www.tourhosts.com.au/icer2004/default.asp
  • Kube T, Maier P, Hansen L, Agostini H: Mouse angiography with a scanning laser ophthalmoscope: Visualisation of the retinal and choroidal vasculature in experimental proliferative retinopathy Invest Ophth Vis Sci, 2004; 45 (ARVO Meeting). : http://www.arvo.org
  • Kube T, Sutter M, Hansen L, Trittler R, Hauser L, Agostini H: Qualitätsanalyse verschiedener Zubereitungen von Triamcinolon-Acetonid-Kristallen für die intravitreale Therapie 2004 (DOG). : http://www.dog.org/2004/556_d.html
  • Schimitzek T, Hansen LL, Agostini HT: Case report of a complex vascular abnormality with an angiomatosis retinae and a macroaneurysm in the macula 2004 (DOG). : http://www.egms.de/en/meetings/dog2004/04dog638.shtml
  • Kube T, Unsöld A, Hansen L, Agostini H: Mouse fundus angiography with a scanning laser ophthalmoscope: Simultaneous fluorescein and indocyanin-green imaging Ophthalmic Res, 2002; 34 (02) Suppl. 1: 112 (EVER 2002 Alicante Spain). : http://www.ever.be
  • Boden KT, Fiedler U, Marmé D, Hansen LL, Agostini HT: Therapie der angioproliferativen Retinopathie mit löslichem VEGF- und Angiopoietin-Rezeptor im Mausmodell. Ophthalmologe, 2001; 98 Suppl. S1: 23.
  • Eberwein P, Stoner GL, Hansen LL, Agostini HT: Nachweis des JC-Virus in Augen HIV-infizierter Patienten. Ophthalmologe, 2001; 98 Suppl. S1: 35.
  • Agostini HT, Auw-Hädrich C, Sundmacher R, Witschel H: Beningnes fibröses Histiozytom als Limbustumor. Ophthalmologe, 2000; 97 Suppl.1: 133 (98. Tagung der DOG).
  • Schlunck G, Agostini HT, Hansen LL: Retinal pigment epithelial cells express semaphorin and neuropilin genes. Invest Ophth Vis Sci, 2000; 41: S838 (ARVO).
  • Agostini HT, Mittelviefhaus H: Sektorförmige bullöse Hornhautdegeneration nach perforierender Glassplitterverletzung Ophthalmologe, 1999; 96 Suppl.1: S17.
  • Reis A, Sundmacher R, Althaus C, Agostini HT, Tintelnot K, Seibold M: Voriconazol - ein neues hochwirksames Antimykotikum bei okulärer Schimmelpilzinfektion Ophthalmologe, 1999; 96 Suppl. 1: S149.